ADA	Antidrug antibodies
Alb	Albumin
ALK	Alkaline phosphatase
AUC	Area under the plasma concentration–time curve
BID	Twice a day
BIW	Twice a week
BSA	Body Surface Area
BW	Body weight
Cavg	Average concentration
Cmax	Maximum concentration
CMT	Compartment
CL	Clearance
CL/F	Apparent clearance
Cr	Creatinine
CrCL	Creatinine clearance
CRP	Baseline C-reactive protein level
Ctrough	Minimum trough concentration
D	Day
DB	Diabetes
DLQI	Dermatologic Life Quality Index
DNA	Deoxyribonucleic acid
EC50	Serum drug concentration causing 50% of the maximum effect
Emax	Maximum drug effect
E–R	Exposure–response
Fc	Fragment crystallizable
FcγR	Fcγ receptor
FcRn	Neonatal Fc receptor
γ	Hill’s coefficient
hs-CRP	High-sensitivity C-reactive protein
HTA	Hypertension
IC50	Median serum drug concentration causing 50% of the maximum inhibitory effect
IFN	Interferon
IIV	Inter-individual variability
IL	Interleukin
IM	Intramuscular
IV	Intravenous
ka	Absorption rate constant
Km	Michaelis–Menten constant
kin	Formation rate of psoriatic skin lesions
kout	Remission rate of psoriatic skin lesion
LE	Linear elimination
mAb	Monoclonal antibody
mDC	Myeloid dendritic cell
MM	Mixture model
MTX	Past methotrexate use
NF- κB	Nuclear factor kappa B
NLE	Nonlinear elimination
NR	Non-responder patients
OR	Oral
PASI	Psoriasis Area Severity Index
PASI75-W12	PASI75 responder status at the week 12 primary
PGA	Physician Global Assessment
PDE4	Phosphodiesterase-4
PD	Pharmacodynamic
PK	Pharmacokinetics
PK/PD	Pharmacokinetics/pharmacodymamics
PLBM	Maximum placebo effect
PP	Palmoplantar psoriasis.
PsA	Psoriatic arthritis
Pso	Psoriasis
Q	Intercompartmental transfer clearance
QD	Every day
QW	Every week
Q2W	Once every 2 weeks
Q4W	Once every 4 weeks
Q8W	Once every 8 weeks
Q12W	Once every 12 weeks
R	Responder patients
RSE	Relative standard error
SC	Subcutaneous
SM	Single model
SMDs	Small-molecule drugs
sPGA	Static Physician Global Assessment
TMDD	Target mediated drug disposition
TDM	Therapeutic drug monitoring
TID	Three times a day
Th	T helper lymphocytes
TNF-α	Tumor necrosis factor alpha
URI	Upper respiratory infection
VC	Central volume of distribution
V/F	Apparent volume of distribution
Vmax	maximal velocity for nonlinear elimination
VPz	Peripheral volume of distribution
W	Week